arGEN-X SE Files 6-K with H1 2025 Financials

Ticker: ARGX · Form: 6-K · Filed: Jul 31, 2025 · CIK: 1697862

Sentiment: neutral

Topics: financial-reporting, sec-filing, equity

TL;DR

arGEN-X SE dropped their Q2 2025 financials, showing equity and reserve details.

AI Summary

On July 31, 2025, arGEN-X SE filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the first half of 2025 and the full year 2024, detailing aspects of their equity and reserves. Specific figures for issued capital, share premium, retained earnings, and other reserves are provided as of December 31, 2023, and for the period ending June 30, 2025.

Why It Matters

This filing provides investors with updated financial information for arGEN-X SE, crucial for assessing the company's performance and financial health during the first half of 2025.

Risk Assessment

Risk Level: low — This is a routine financial filing (6-K) providing standard financial disclosures, not indicating any unusual risks.

Key Numbers

Key Players & Entities

FAQ

What is the reporting period for this 6-K filing?

The conformed period of report is June 30, 2025.

When was this 6-K filing submitted to the SEC?

The filing was submitted on July 31, 2025.

What is the Central Index Key (CIK) for ARGENX SE?

The CIK for ARGENX SE is 0001697862.

What type of business is ARGENX SE primarily involved in?

ARGENX SE is in the Biological Products industry, specifically excluding diagnostic substances.

Does the filing provide financial data for the first half of 2025?

Yes, the filing includes data for the period from January 1, 2025, to June 30, 2025.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on July 31, 2025 regarding ARGENX SE (ARGX).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing